The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism

F. Tonelli, M. Alossaimi, L. Williamson, R.J. Tate, D.G. Watson, E. Chan, R. Bittman, N.J. Pyne, S. Pyne

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Sphingosine kinase catalyses the formation of sphingosine 1-phosphate and is linked with androgen receptor signaling in prostate cancer cells. Therefore, we investigated the effect of sphingosine kinase inhibitors on androgen receptor expression. Androgen-sensitive LNCaP cells were treated with SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole), which inhibits sphingosine kinases 1 and 2 activity, and the effect on androgen receptor expression was measured. Treatment of cells with SK1 inhibitors reduced the expression of the androgen receptor and prostatic specific antigen, while (R)-FTY720 methyl ether (a sphingosine kinase 2 specific inhibitor) at a concentration that eliminates sphingosine kinase 2 from cells had no significant effect on androgen receptor expression. The effect of SKi on androgen receptor expression was independent of the SKi-induced proteasomal degradation of SK1 and was post-translational, although androgen receptor mRNA transcript was reduced. Fumonisin B1 (a ceramide synthase inhibitor) also failed to reverse the effect of SKi on androgen receptor expression, thereby excluding a role for ceramide derived from the salvage pathway. The effect of SKi on androgen receptor expression was reversed by N-acetylcysteine, which was used to scavenge reactive oxygen species. Inhibition of sphingosine kinase 1 activity abrogates androgen receptor signaling via an oxidative stress-induced, p53-independent mechanism in prostate cancer cells. Therefore, SK1 inhibitors may offer therapeutic potential in promoting the removal of the AR receptor from prostate cancer cells, resulting in an increased efficacy which is likely to be superior to inhibitors that simply reversibly inhibiting AR signaling.
LanguageEnglish
Pages1497-1505
Number of pages9
JournalBritish Journal of Pharmacology
Volume168
Issue number6
Early online date25 Feb 2013
DOIs
Publication statusPublished - 1 Mar 2013

Fingerprint

Thiazoles
Androgen Receptors
Oxidative Stress
Prostatic Neoplasms
sphingosine kinase
Methyl Ethers
Ceramides
Acetylcysteine
Androgens
Reactive Oxygen Species
Antigens

Keywords

  • sphingosine kinase inhibitor
  • 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole
  • androgen receptor expression
  • oxidative stress-dependent mechanism
  • reactive oxygen species
  • prostate cancer

Cite this

@article{aeed4187a3784c01a402c983fc215995,
title = "The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism",
abstract = "Sphingosine kinase catalyses the formation of sphingosine 1-phosphate and is linked with androgen receptor signaling in prostate cancer cells. Therefore, we investigated the effect of sphingosine kinase inhibitors on androgen receptor expression. Androgen-sensitive LNCaP cells were treated with SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole), which inhibits sphingosine kinases 1 and 2 activity, and the effect on androgen receptor expression was measured. Treatment of cells with SK1 inhibitors reduced the expression of the androgen receptor and prostatic specific antigen, while (R)-FTY720 methyl ether (a sphingosine kinase 2 specific inhibitor) at a concentration that eliminates sphingosine kinase 2 from cells had no significant effect on androgen receptor expression. The effect of SKi on androgen receptor expression was independent of the SKi-induced proteasomal degradation of SK1 and was post-translational, although androgen receptor mRNA transcript was reduced. Fumonisin B1 (a ceramide synthase inhibitor) also failed to reverse the effect of SKi on androgen receptor expression, thereby excluding a role for ceramide derived from the salvage pathway. The effect of SKi on androgen receptor expression was reversed by N-acetylcysteine, which was used to scavenge reactive oxygen species. Inhibition of sphingosine kinase 1 activity abrogates androgen receptor signaling via an oxidative stress-induced, p53-independent mechanism in prostate cancer cells. Therefore, SK1 inhibitors may offer therapeutic potential in promoting the removal of the AR receptor from prostate cancer cells, resulting in an increased efficacy which is likely to be superior to inhibitors that simply reversibly inhibiting AR signaling.",
keywords = "sphingosine kinase inhibitor, 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole, androgen receptor expression, oxidative stress-dependent mechanism, reactive oxygen species, prostate cancer",
author = "F. Tonelli and M. Alossaimi and L. Williamson and R.J. Tate and D.G. Watson and E. Chan and R. Bittman and N.J. Pyne and S. Pyne",
note = "{\circledC} 2012 The Authors. British Journal of Pharmacology {\circledC} 2012 The British Pharmacological Society.",
year = "2013",
month = "3",
day = "1",
doi = "10.1111/bph.12035",
language = "English",
volume = "168",
pages = "1497--1505",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
number = "6",

}

The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. / Tonelli, F.; Alossaimi, M.; Williamson, L.; Tate, R.J.; Watson, D.G.; Chan, E.; Bittman, R.; Pyne, N.J.; Pyne, S.

In: British Journal of Pharmacology, Vol. 168, No. 6, 01.03.2013, p. 1497-1505.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism

AU - Tonelli, F.

AU - Alossaimi, M.

AU - Williamson, L.

AU - Tate, R.J.

AU - Watson, D.G.

AU - Chan, E.

AU - Bittman, R.

AU - Pyne, N.J.

AU - Pyne, S.

N1 - © 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Sphingosine kinase catalyses the formation of sphingosine 1-phosphate and is linked with androgen receptor signaling in prostate cancer cells. Therefore, we investigated the effect of sphingosine kinase inhibitors on androgen receptor expression. Androgen-sensitive LNCaP cells were treated with SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole), which inhibits sphingosine kinases 1 and 2 activity, and the effect on androgen receptor expression was measured. Treatment of cells with SK1 inhibitors reduced the expression of the androgen receptor and prostatic specific antigen, while (R)-FTY720 methyl ether (a sphingosine kinase 2 specific inhibitor) at a concentration that eliminates sphingosine kinase 2 from cells had no significant effect on androgen receptor expression. The effect of SKi on androgen receptor expression was independent of the SKi-induced proteasomal degradation of SK1 and was post-translational, although androgen receptor mRNA transcript was reduced. Fumonisin B1 (a ceramide synthase inhibitor) also failed to reverse the effect of SKi on androgen receptor expression, thereby excluding a role for ceramide derived from the salvage pathway. The effect of SKi on androgen receptor expression was reversed by N-acetylcysteine, which was used to scavenge reactive oxygen species. Inhibition of sphingosine kinase 1 activity abrogates androgen receptor signaling via an oxidative stress-induced, p53-independent mechanism in prostate cancer cells. Therefore, SK1 inhibitors may offer therapeutic potential in promoting the removal of the AR receptor from prostate cancer cells, resulting in an increased efficacy which is likely to be superior to inhibitors that simply reversibly inhibiting AR signaling.

AB - Sphingosine kinase catalyses the formation of sphingosine 1-phosphate and is linked with androgen receptor signaling in prostate cancer cells. Therefore, we investigated the effect of sphingosine kinase inhibitors on androgen receptor expression. Androgen-sensitive LNCaP cells were treated with SKi (2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole), which inhibits sphingosine kinases 1 and 2 activity, and the effect on androgen receptor expression was measured. Treatment of cells with SK1 inhibitors reduced the expression of the androgen receptor and prostatic specific antigen, while (R)-FTY720 methyl ether (a sphingosine kinase 2 specific inhibitor) at a concentration that eliminates sphingosine kinase 2 from cells had no significant effect on androgen receptor expression. The effect of SKi on androgen receptor expression was independent of the SKi-induced proteasomal degradation of SK1 and was post-translational, although androgen receptor mRNA transcript was reduced. Fumonisin B1 (a ceramide synthase inhibitor) also failed to reverse the effect of SKi on androgen receptor expression, thereby excluding a role for ceramide derived from the salvage pathway. The effect of SKi on androgen receptor expression was reversed by N-acetylcysteine, which was used to scavenge reactive oxygen species. Inhibition of sphingosine kinase 1 activity abrogates androgen receptor signaling via an oxidative stress-induced, p53-independent mechanism in prostate cancer cells. Therefore, SK1 inhibitors may offer therapeutic potential in promoting the removal of the AR receptor from prostate cancer cells, resulting in an increased efficacy which is likely to be superior to inhibitors that simply reversibly inhibiting AR signaling.

KW - sphingosine kinase inhibitor

KW - 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole

KW - androgen receptor expression

KW - oxidative stress-dependent mechanism

KW - reactive oxygen species

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84874425286&partnerID=8YFLogxK

U2 - 10.1111/bph.12035

DO - 10.1111/bph.12035

M3 - Article

VL - 168

SP - 1497

EP - 1505

JO - British Journal of Pharmacology

T2 - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -